Nurix Therapeutics(NRIX)
BRISBANE, CABiotechnology
Focus: Nurix is a public oncology-focused biotech specializing in small molecules and protein degradation technologies. The company is early-stage with $77M in FY2025 revenue and a pipeline concentrated in Phase 1 programs.
Profile data last refreshed 4h ago · AI intelligence enriched 2w ago
Funding Stage
PUBLIC
Open Jobs
10+3 this month
Stable — net +3 jobs in 30d
5 added, 2 removed. Backfill posture.
Should You Work at Nurix Therapeutics?
AI assessmentBest suited for technical specialists (medicinal chemists, translational scientists) seeking hands-on protein degradation expertise with acceptable early-stage risk; less ideal for those seeking stability, career progression, or near-term regulatory wins.
Why Work Here
- Cutting-edge protein degradation platform with differentiated mechanism of action in oncology — rare technical specialization valued across industry
Data completeness
3/9 — Basic
Company HealthStrong
Pipeline
Early-stage
8 total
LOE Risk
Protected
No near-term cliffs
Hiring
Stable
Revenue
$77M
Pipeline & Clinical Trials
NX-5948
Healthy VolunteerClinical Trials (3)
NCT07516093Study of NX-5948 Versus Pirtobrutinib in R/R CLL/SLL
Phase 3Help build intelligence for Nurix Therapeutics
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.